NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Investor082,

NICE is practical and uses a little common sense to value treatments. The cost/benefit ratio actually means something to those who are frugal and practical. When pricing would limit the number of patients who can benefit, the push will always be to get pricing to where more patients can benefit in the UK. Flaskworks development had to happen sooner rather than later because of the importance of this treatment as a potential base immunotherapy for all future cancer patients and the need for cell therapy to advance to the mainstream as a safe effective treatment but too highly qualified labor intensive to make widely available. NWBO is leading the way so everything gets held up while waiting in their advancement because big pharma never chose to value this tech properly. Best wishes.